Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib for immune dysregulation in common variable immunodeficiency
2024-517725-93-00Phase 2Completed
- Sponsor
- Pharming Group
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of leniolisib in common variable immunodeficiency (CVID), sponsored by Pharming Group. Primary endpoint: Adverse events. Started May 2025; status: completed.
02
Drugs
leniolisib
03
Conditions
common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on 2024-517725-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517725-93-00.